Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

被引：0
|
作者：
Backes, F. [1 ]
Richardson, D. [2 ]
McCann, G. [1 ]
Salani, R. [1 ]
Eisenhauer, E. [1 ]
Fowler, J. [1 ]
Copeland, L. [1 ]
Cohn, D. [1 ]
O'Malley, D. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Texas SW, Dallas, TX USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.226
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
225
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [41] Bevacizumab in the Treatment of Ovarian Cancer
    Heitz, Florian
    Harter, Philipp
    Barinoff, Jana
    Beutel, Bianca
    Kannisto, Paevi
    Grabowski, Jacek P.
    Heitz, Julia
    Kurzeder, Christian
    du Bois, Andreas
    ADVANCES IN THERAPY, 2012, 29 (09) : 723 - 735
  • [42] Bevacizumab in Ovarian Cancer REPLY
    Oza, Amit M.
    Swart, Ann Marie
    Perren, Timothy J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13): : 1258 - 1258
  • [43] Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
    Lee, Jung-Min
    Annunziata, Christina M.
    Hays, John L.
    Cao, Liang
    Choyke, Peter
    Yu, Minshu
    An, Daniel
    Turkbey, Ismail Baris
    Minasian, Lori M.
    Steinberg, Seth M.
    Chen, Helen
    Wright, John
    Kohn, Elise C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 88 - 94
  • [44] EVALUATION OF REBOUND ASCITES FOLLOWING DISCONTINUATION OF BEVACIZUMAB IN RECURRENT OVARIAN CANCER
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Spriggs, D.
    Aghajanian, C.
    Sabbatini, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 309 - 309
  • [45] The efficacy and toxicity of bevacizumab plus genicitabine in patients with recurrent ovarian cancer
    Bevis, K. S.
    Numnum, T. M.
    Shipman, K. A.
    Makhija, S.
    Barnes, M. N.
    Straughn, J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S119 - S120
  • [46] CA125 response to bevacizumab in recurrent ovarian cancer.
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Diaz, J. P.
    Tew, W. P.
    Hensley, M. L.
    O'Flaherty, C.
    Aghajanian, C.
    Spriggs, D. R.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
    Musa, Fernanda
    Pothuri, Bhavana
    Blank, Stephanie V.
    Ling, Huichung T.
    Speyer, James L.
    Curtin, John
    Boyd, Leslie
    Li, Xiaochun
    Goldberg, Judith D.
    Muggia, Franco
    Tiersten, Amy
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 279 - 284
  • [48] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [49] Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer
    Cong, Jianglin
    Liu, Riming
    Hou, Jianqing
    Wang, Xiuli
    Jiang, Haiyang
    Wang, Jing
    JOURNAL OF BUON, 2019, 24 (03): : 1003 - 1008
  • [50] Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer
    Liotta, Margaret
    Rose, Peter G.
    Escobar, Pedro F.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (02) : 308 - 309
12345